Loading...

Matthew Gubens, MD

TitleAssociate Professor
InstitutionUniversity of California San Francisco
DepartmentMedicine
Address1600 Divisadero
San Francisco CA 94115
Phone415-353-9674
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Yale UniversityB.A.1997Ethics, Politics and Economics
    Harvard School of Public HealthM.S.2000Health Policy and Management
    Stanford UniversityM.D.2005School of Medicine
    University of California, San FranciscoResidency 2008School of Medicine - Internal Medicine
    Stanford UniversityFellowship2011School of Medicine - Medical Oncology

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Global Health
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Gubens M, Chuang JC, Akerley W, Langer CJ, Clément-Duchêne C, San Pedro-Salcedo M, Colevas AD, Dragnev K, Socinski MA, Wakelee HA. A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. J Thorac Dis. 2018 Jan; 10(1):219-227. PMID: 29600052.
      View in: PubMed
    2. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens M, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704. PMID: 29106415.
      View in: PubMed
    3. Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens M, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018 Jan; 19(1):58-64. PMID: 28645632.
      View in: PubMed
    4. Gubens M. Immunotherapies for Lung Cancer. J Natl Compr Canc Netw. 2017 May; 15(5S):692-695. PMID: 28515246.
      View in: PubMed
    5. Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens M, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017 05; 5(5):417-424. PMID: 28411193.
      View in: PubMed
    6. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens M, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 04; 15(4):504-535. PMID: 28404761.
      View in: PubMed
    7. Jonsson VD, Blakely CM, Lin L, Asthana S, Matni N, Olivas V, Pazarentzos E, Gubens M, Bastian BC, Taylor BS, Doyle JC, Bivona TG. Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Sci Rep. 2017 Mar 13; 7:44206. PMID: 28287179.
      View in: PubMed
    8. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov; 17(11):1497-1508. PMID: 27745820.
      View in: PubMed
    9. Ramalingam S, Hui R, Gandhi L, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Leighl N, Aggarwal C, Horn L, Patnaik A, Middleton GW, Gubens M, Hellmann M, Soria JC, Lubiniecki GM, Zhang J, Piperdi B, Garon EB. P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy. J Thorac Oncol. 2016 Oct; 11(10S):S241-S242. PMID: 27676573.
      View in: PubMed
    10. Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Lett. 2016 09 28; 380(1):144-52. PMID: 27343980.
      View in: PubMed
    11. Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol. 2015 Nov; 151(11):1206-1212. PMID: 26222619.
      View in: PubMed
    12. Magbanua MJ, Pugia M, Lee JS, Jabon M, Wang V, Gubens M, Marfurt K, Pence J, Sidhu H, Uzgiris A, Rugo HS, Park JW. A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay. PLoS One. 2015; 10(10):e0141166. PMID: 26496203; PMCID: PMC4619669.
    13. Gubens M, Burns M, Perkins SM, Pedro-Salcedo MS, Althouse SK, Loehrer PJ, Wakelee HA. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. Lung Cancer. 2015 Jul; 89(1):57-60. PMID: 26009269.
      View in: PubMed
    14. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015 May 21; 372(21):2018-28. PMID: 25891174.
      View in: PubMed
    15. Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens M, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG. NF-?B-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 2015 Apr 07; 11(1):98-110. PMID: 25843712; PMCID: PMC4394036.
    16. Smith DC, Eisenberg PD, Manikhas G, Chugh R, Gubens M, Stagg RJ, Kapoun AM, Xu L, Dupont J, Sikic B. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014 Dec 15; 20(24):6295-303. PMID: 25324140.
      View in: PubMed
    17. Woodard GA, Gubens M, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ. Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer. Clin Lung Cancer. 2014 Nov; 15(6):426-32. PMID: 25258195.
      View in: PubMed
    18. Riess JW, Nagpal S, Iv M, Zeineh M, Gubens M, Ramchandran K, Neal JW, Wakelee HA. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clin Lung Cancer. 2014 May; 15(3):202-6. PMID: 24524822.
      View in: PubMed
    19. Gubens M. Treatment updates in advanced thymoma and thymic carcinoma. Curr Treat Options Oncol. 2012 Dec; 13(4):527-34. PMID: 22961051.
      View in: PubMed
    20. Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol. 2012 Oct 01; 30(28):3507-15. PMID: 22949151.
      View in: PubMed
    21. Neal JW, Gubens M, Wakelee HA. Current management of small cell lung cancer. Clin Chest Med. 2011 Dec; 32(4):853-63. PMID: 22054891.
      View in: PubMed
    22. Nguyen TT, Gubens M, Arber DA, Advani R, Juretzka M, Aziz N. Lymphoma in pregnancy initially diagnosed as vaginal intraepithelial neoplasia and lichen planus. Obstet Gynecol. 2011 Aug; 118(2 Pt 2):486-9. PMID: 21768862.
      View in: PubMed
    23. Gubens M, Wakelee HA. Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis. Lung Cancer (Auckl). 2010; 1:63-76. PMID: 28210107.
      View in: PubMed
    24. Heidenreich PA, Gubens M, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol. 2004 Mar 17; 43(6):1019-26. PMID: 15028361.
      View in: PubMed